Massachusetts Life Sciences Center’s Post

Early planning sets up long-term success. Meet Paul Sohal and Nigel Cawthon during #JPM24 to discuss how Corval can jumpstart your biopharma commercialization planning.

Who's coming to #jpm next week? Let's connect and discuss how technology can take your commercialization planning to the next level. #biotech #healthtch #jpm2024 #jpmorgan #commercialization #biopharma

To Early-Stage BioPharma companies who want to grow in or entering the USA Market.

Thoughts on this? >> Siegfried nabs US site from Curia; Merck KGaA pumps €62M more into its HQ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #healthcare #pharmaceutical #pharma

Thoughts on this? >> Siegfried nabs US site from Curia; Merck KGaA pumps €62M more into its HQ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #healthcare #biotech #pharmaceutical

📣We’re excited to announce that we have raised $21M in the first close of our Series B investment round! The global OOC market is growing rapidly, in part, by the need for biopharmaceutical companies to improve the efficiency and success rate of innovative drug R&D, and recent legislative changes, such as the US FDA Modernization Act 2.0. At CN Bio, we have strategically positioned ourselves to respond to this need and meet the increasing demand for our PhysioMimix® OOC technology and research services. Together, we are working to provide deeper, clinically-relevant insights into early-stage preclinical drug discovery in a wider range of application areas, whilst reducing reliance on animal models. We are proud to have received recognition from our major shareholder, 中南創發 CN INNOVATIONS and new institutional investors such as Bayland Capital 康君资本 The investment is a testament to our team’s hard work and dedication to best supporting our customers to bring drugs to patients more quickly, more cost-effectively, and through less animal experimentation. Moving forward, we plan to use this investment to capitalize on a global growth opportunity and deliver an ambitious commercial expansion strategy to help drive this vision forward. 👉 Read more about the news, here: https://bit.ly/3W5V0xz #PressRelease #Investment #OrganOnAChip #DrugDevelopment

Biopharma M&A deals are on the rise! According to a recent report from Leerink Partners, there were 13 deals in the first quarter of 2024, compared to just 6 during the same period last year. This trend highlights the growing importance of M&A as a top exit route for pre-commercial biopharma companies looking for validation and attention. In the last twelve months through March 2024, there were a total of 47 biopharma M&A deals, compared to 42 in the previous year. Stay tuned for more insights. #Biopharma #PharmaTell #CompetitiveIntelligence #MarketIntelligence Read more on BioPharma deals in Q1:

Thoughts on this? >> AstraZeneca-allied Eccogene targets early 2025 Nasdaq IPO with multiple NASH candidates >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #pharma #healthcare

Breaking: Novo Holdings, the investment arm of Novo Nordisk’s parent foundation, has announced a monumental move in the pharmaceutical realm. Novo Holdings is set to acquire Catalent Pharma Solutions for a staggering $16.5 billion in an all-cash transaction. Catalent, a prominent figure in the contract development and manufacturing sector, plays a crucial role in producing Novo Nordisk’s highly sought-after obesity drug Wegovy, which has been experiencing shortages. As part of this landmark agreement, Novo Holdings will divest three Catalent fill-finish sites and associated assets to Novo Nordisk, including locations in Italy, Belgium, and Bloomington, IN. Novo Nordisk will pay a total of $11 billion for these sites, which collectively employ 3,000 individuals and have had prior collaborative relationships with the pharmaceutical giant. "The acquisition complements the significant investments we are already making in active pharmaceutical ingredients facilities, and the sites will provide strategic flexibility to our existing supply network," commented Lars Fruergaard Jørgensen, President and CEO of Novo Nordisk. Catalent, with over 50 global sites and 18,000 employees, has been the focus of strategic review following declining revenue and challenges at some major manufacturing sites. The purchase price of $63.5 per share, representing a premium of 39.1% to the closing price of Catalent’s stock before the review announcement, underscores Novo Holdings' commitment to realizing Catalent's full potential. Novo Holdings CEO Kasim Kutay expressed enthusiasm for the partnership, emphasizing the organization's dedication to fostering productive relationships with all stakeholders. With the deal expected to close by the end of 2024, Catalent will cease trading on NYSE, marking the end of an era for the company that witnessed significant market fluctuations over the years. Novo Holdings owns 28% of the shares in Novo Nordisk by has a 77% of the voting rights. It is an investment group created to manage the wealth of the Novo Nordisk Foundation, which is the world's largest charitable foundation. Source:

Thoughts on this? >> Bristol Myers, Cellares sign global CAR-T deal as biopharma companies look to diversify manufacturing partners  >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #productmarketing #pharmaceutical #healthcare